Sue MacLeman

• Advisor and Non Executive Director MTP sector
• BPharm LLM MMktg FTSE

Sue graduated with a BPharm from the Uni of Queensland in 1984. In addition to pharmacy qualifications, Sue has completed a Masters of Marketing degree at Melbourne Uni (Melbourne Business School), a Masters of Law degree (Deakin University) and is a Fellow of the Australian Academy of Technology & Engineering and is a Fellow/Graduate of AICD.
From 1985-1991 Sue worked in hospital pharmacy roles. In 1991 Sue joined the pharmaceutical industry with Schering Plough. She then went on to work with Amgen and Bristol Myers Squibb in medical, marketing, sales management and business development roles. In 2002 Sue moved to global Vice President role with Agenix Ltd. From 2004 – 2006 she was the CEO of investment and management co. EQiTX Ltd. She was then CEO of RNAi therapeutics publicly listed co. Benitec Ltd including its US and UK subsidiaries . She then went on to be CEO of Progen Pharmaceuticals Ltd including contract manufacturing subsidiary PharmaSynth Pty Ltd and US epigenetics subsidiary EpiPharmaceuticals Inc. Sue was then Senior Vice President Corporate (2011-2013) then Global Head Commercial (2014-2016) for regenerative medicines company Mesoblast Ltd . Sue was the inaugural CEO/MD of MTPConnect (2016-2018) and then Chair (2018-2023). Sue has been a Board member of a number of public and private entities globally including her current appointments as Non Executive Director Planet Innovation Holdings Ltd , Rhythm Biosciences Ltd, HOS Ltd T/A Smartways Logistics, Vital Vector Manufacturing Facility Pty Ltd, ATSE and Omico. Sue is also active on both government and academic and commercial advisory committees.